Immunological Response of Hiv-Infected Children to Highly Active Antiretoviral Therapy at Gondar University Hospital, North-Western Ethiopia by Kokeb, Mehretie & Degu, Getu




ORGINAL ARTICLE   
 
Immunological Response of Hiv-Infected Children to Highly Active 











BACKGROUND: The effectiveness of highly active antiretroviral therapy (HAART) in children has not 
been well studied specially in developing countries where the burden of HIV is high. This study was 
aimed to assess the immunologic response of HIV-infected children to HAART at Pediatric ART Clinic 
Gondar University Hospital.  
METHODS: Institution based cross-sectional study was conducted at the  Pediatric ART Clinic Gondar 
University Hospital from March01-April 30, 2014. The study included 283 HIV-infected children who 
were on HAART for 6 months and above. Medical records of HIV-infected children were reviewed using 
pre-tested questionnaire. CD4 count/percent was collected every 6 months retrospectively. For all 
statistical significance tests, the cut-off value was p<0.05. Poison Regression was used for further 
analysis.  
RESULTS:  The mean age of children was 6.9 years with a standard deviation of 3.4 years. The median 
CD4 count/percent was 232/13%, 450/21%, 540/25% and 608/27% at the time of initiation, 6, 12 and 18 
months of ART, respectively. HAART initiated at higher CD4 count, good adherence and HIV status 
disclosure were found to have positive effects for immunological response. 
CONCLUSION: The study revealed that there was good Immunological response to ART, and that the 
maximum response was in the 1
st
 6 months of ART. Low CD4 count at initiation, undisclosed HIV status 
and lack of good adherence were found to cause low immunological response to HAART.  
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INTRODUCTION   
 
About 2.1 million children of less than 15 years 
old are living with HIV worldwide. Of these, 90% 
live in sub-Saharan Africa and about 135,813 live 
in Ethiopia (1). ART has radically changed the 
natural course of HIV infection in countries where 
it has been successfully implemented and HIV-
infected infants and children now survive to 
adolescence and adulthood (2). In resource-limited 
countries, despite many challenges to program 
implementation, committed efforts have resulted 
in remarkable progress in making ART accessible 
to  HIV-infected children. Significant challenges 
to  the scale-up of pediatric care and treatment 
include: limited screening of HIV-infected 
children, lack of affordable and simple diagnostic 
tests, lack of trained human resources, insufficient 
advocacy and lack of understanding that ART is 
efficacious in children (3, 4). WHO recommended 
that first line ART drugs are having good result in 
increasing the CD4 count and suppressing the 
plasma viral load in children in resource-
constrainedregions,. Making the ART drugs free 
of charge is related to good outcome of children 
(5, 6, 7). Clinical response with increment in 
anthropometric parameters, lowering of WHO 
clinical stages and reduction in incidence of 
opportunistic infections were achieved after 
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HAART in children (8, 9, 10). The rationale for 
conducting this research was the fact that there is 
no adequate study done on immunologic response 
of HIV-infected children in Ethiopia, and no study 
has been done at Gondar University Hospital In 
addition, the number of children being started on 
HAART is increasing in Ethiopia, which 
necessitates clear knowledge about the treatment 
response. The major objective of our study was to 
assess the immunologic response of HIV-infected 
children to Highly Active Antiretroviral Therapy 
focusing on the periodic evaluation of CD4 
count/percent. 
  
METHOD AND MATERIALS 
 
An institution based cross-sectional study was 
conducted at the Pediatric ART Clinic, Gondar 
University Hospital, from March-April 2014 to 
assess the immunologic response of HIV-infected 
children to HAART. The medical records of all 
HIV-infected children having followup at Gondar 
University Hospital, Pediatric ART Clinic, and 
took HAART for 6 months or more were 
reviewed. Sample size was calculated to be 340 
which was obtained by systematic random 
sampling technique taking every 4
th
 record number 
from a total of 1360 HIV-infected children taking 
HAART for 6 months or more. HIV-infected 
children with no documented CD4 results at 
initiation and/or 6 months were excluded from the 
study. Out of 340 medical records, 57 were 
excluded from analysis because of lack of 
documented CD4 results at initiation (30 cases) 
and at 6 months of HAART (27cases). Medical 
records of the sampled population were collected 
by two clinical nurses working at the ART Clinic 
(one working at Pediatric ART, one working at 
Adult ART) under the supervision of one 
physician. The collected patient records were 
reviewed based on the required variables: age, 
WHO clinical stage (1-4) at initiation and CD4 
count/percent at initiation, adherence, relation 
with the care taker, parental HIV status, disclosure 
status, and survival status of mother.  The 
questionnaire was pretested and structured; the 
pretest was done on 25 patients (8% of the 
sample) who were not included in the study. All 
data collected for the study were double entered in 
SPSS by two different data entry clerks and 
verified using the validation program. In the 
analysis, the socio-economic and demographic 
data were related with the immunological results 
of HIV-infected children taking HAART. For all 
statistical significance tests, the cut-off value was 
p<0.05. Poison Regression was used for further 
analysis of the outcome of HIV-infected children. 
The problem of extra-poison variation was 
checked using the usual assessment mechanism, 
and there was no over dispersion as the deviance 
(i.e. -2log likelihood) divided by the 
corresponding degree of freedom was very close 
to 1. Ethical approval for this study was secured 
from internal review board at the University of 
Gondar, College of Medicine and Health Sciences. 
Permission letter to conduct the research was 
obtained from Gondar University Hospital. 
Confidentiality was secured by coding each 





A total of 283 HIV-infected children who were on 
ART for 6 months or more were included in the 
study. Of these,  146(51.6%) were males while the 
remaining 137 (48.4 %) were females. Most of the 
cases were from Gondar Town which consisted of 
75%(212/283). The remaining 25% were out of 
the town of Gondar (Table 1).The age distribution 
showed that 185(65.4%),  85(30%), and 13 (4.6 
%) children were 5-14yrs, 1-5yrs and below 1 
year, respectively. The Minimum age at initiation 
was 6 months and the maximum was 17years with 
a median of 6.9 years and a standard deviation of 
3.4 years. The study showed that 31.1 %( 88/283) 
of mothers had unknown HIV status and the 
remaining 68.9% were confirmed HIV- positive; 
140(49.5%), 119(42%), and 24 (8.5%) fathers 
were HIV-positive, unknown status and negative, 
respectively (Table-1). The majority of children 
were tested for their HIV-infection status  because 
of illness  consisting of 213 (75.3%) and the rest 
40(14.1%), 10(3.5%) and 20(7.1%) were tested 
because parent/s positive for HIV, for VCT and 
Provider-initiated Testing and counseling, 
respectively. In this study, 57(20.2 %), 
135(47.7%), 65(22.9 %) and 26(9.2%) of the 
children were at clinical stages 4, 3, 2 and 1, 
respectively at initiation of ART.Clinical Stage 1 
was observed in 149(53.9 %) at 6 months, 
147(55.5 %) at 12 months and 231(78%) at 18 
months of HAART (Figure 1).The median CD4 
count and CD4 percent at initiation were 232 and 
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13%, respectively with a maximum CD4 count of 
2300 and a maximum CD4 percent of 96% and the 
minimum CD4 count and CD4 percent were 2 and 
0.15%, respectively. The median CD4 count and 
percent were 450/21%, 540/25% and 608/27% at 6 
months, 12 months and 18 months of HAART, 
respectively (Table 2).  
 
Table1: Socio-demographic characteristics of the study population from march 01-April 30, 2014 at 
Pediatric ART Clinic, Gondar University Hospital. 
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Educational status of Mother 
Could not read / write 
















Educational Status of Father 
Could not read/write 



















Figure 1: Clinical stages at initiation, 6 months, 12 months and 18 months of ART, GUH 





    Table 2: Median CD 4 count/percent at 0, 6, 12 and 18 months of ART 
                                         Months on HAART 
Median 0(at initiation) 6 12 18 






CD4 percent 13(Max: 96, Min:  0.15%) 21(Max: 89, 
Min: 0.2%) 
25(Max:94, Min: 3 %) 27(Max:99, Min: 
10 %) 
 
In this study, 6(2.1%), 9(3.3%) and 1(0.4%) 
children died at 6,12 and 18 months of HAART, 
respectively, making a total of 16(5.7%)  deaths 
during the 18 months followup. Disclosure of HIV 
status was given to 20(7.1%), 29(10.5%), 
34(12.8%), and 43 (16.4%) of children at the 
initiation, 6, 12 and 18 months of HAART, 
respectively (Table 3). Adherence was found to be 
good during the whole 18 months period and 
95.5%, 97.8% and 97.6% of children at 6, 12 and 
18 moths of HAART were reported to have good 
adherence, respectively, according to the Ethiopian 
Pediatric ART guideline 2008. The median CD4 
percent at 6 months of HART was found to be 
24.1%, 20.1% and 18.1% when initiated in children 
of age below 3years, 3-5years and above 5years, 
respectively. Median CD4 percent at 6 months of 
HAART was 16.4%, 24.6% and 34% when 
treatment was initiated at CD4 count of less than 
200, 200-500 and more than or equal to 500, 
respectively. Median CD4 percent at 6 months of 
treatment was 20.2%, 10.7% and 9.2% in children 
with Good, Fair and Poor adherence, respectively. 
The median CD4 percent at 6 moths of HAART 
was found to be 20.8%, 24.8%, 12.6% and 8.1% in 
children with clinical stage of I, II, III & IV at 
initiation, respectively (Table 4).  
Initial CD4 count, disclosure of HIV status and 
adherence were found to have statistically 
significant associations with CD4 response at 6 
months of HAART. In this regard, children with 
higher initial CD4 count were found to have good 
increment of CD4 at 6 months of HAART. Children 
whose disclosure was given at initiation of HAART 
were observed to have about 34% increase in CD4 
count compared to those who did not get their status  
disclosed at 6 months at 
 
Table 4: Median CD4 percent at 6 months of 






6months of ART 
Age 
Less than 3years 
3-5years 
> 5years 
CD4 count at initiation 






























HAART. On the other hand, those with poor 
adherence were found to have a 16% lower CD4 
increment compared to those with good adherence. 
Age showed a marginal significance while child’s 
sex, maternal death, and clinical stage did not show 
a statistically significant association with the 
outcome variable (Table 5). 
 




                          Months on HAART 
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( rate ratio) 
95% C.I. 
 
   
P-value 
Initial CD4 count  0.0099 1.01 1.001 1.019 <0.001* 
Age -.0222 0.978 0.955 1.003 0.081 
Sex -.0377 0.963 0.825 1.125 0.636 
Mother alive -.1031 0.902 0.764 1.066 0.226 
Disclosure 0.2919 1.339 1.073 1.672 0.01* 
Adherence -.1732 0.841 0.730 0.969 0.017* 
Clinical stage 1 0.0315 1.032 0.794 1.34 0.816 
Clinical stage 2 -.1087 0.897 0.747 1.078 0.247 




The primary aim of this study was to assess the 
immunological response of HIV-infected children to 
HAART after 6 months of treatment. Our study showed 
that the majority of children (75.3%) were diagnosed for 
HIV because they were sick and only few (7.1%) were 
diagnosed by Provider-Initiated Counseling and Testing. 
This shows that children are diagnosed after they get 
deteriorated which may be a reason for poor response to 
HAART. Thus, there should be strong PITC activity to 
catch children before advanced HIV disease. The 
majority (65.4%) of the children were diagnosed for HIV 
after 5 years of age with the median age of 6.9 years, 
which is lower than a study in Kenya which revealed 
mean age of 8.5 years (1) but significantly higher than a 
study in USA where the median age at initiation was 2.7 
years (2). This shows that initiation of HAART in the 
study area is not being done in early age which is a very 
important factor for response to HAART. This study 
revealed that the majority of the children (67.9%) were 
started on HAART at severe clinical stage (Stage 3 or 4) 
which is almost comparable with a study from South 
Africa which revealed 62.7% were in severe clinical 
stage at initiation (3) but higher thana study from India 
which revealed only 40.3% were at severe stage when 
they were initiated(4). This indicates that children are not 
being started on HAART earlier which may be due to 
late diagnosis of HIV in children. The median CD4 
count/CD4 percent at initiation was 232(13%), with 
maximum CD4 count/CD4 percent of 2300/23%, and the 
minimum CD4 count/ CD4 percent was 2/0.15%. The 
median CD4 counts/percents were 450/21%, 540/25% 
and 608/27% at 6 months, 12 months and 18 months of 
ART, respectively. Significant increment was shown 
during the first 6 months of therapy (from 232/13% to 
450/21%). 
The response rate at 6 months is almost similar with 
the analysis done in South Africa; a similar finding was 
also reported from Thailand (3, 9). This finding is in 
consistent with other studies showing a significant raise 
during the first 6 months of HAART (6, 7, 8). This is 
good evidence that children are responding well to 
HAART, and in this study, the CD4 at 6 months was 
higher compared to the same analysis in Kenya which 
revealed median of 293 at 6 months of HAART (6). 
Immunological response was found to be better in 
children less than 5 years compared to those more than 5 
years at initiation of HAART (median CD4 percent at 6 
months was 24.1% vs 18.4%). This is comparable with 
the European collaborative study which revealed that 
CD4 response was significantly higher when HAART is 
started before 5 moths of age (10). This is evidence that 
children should be started on treatment in early age to 
have good immunological response which is most likely 
related to immunological deterioration if not treated 
earlier. The CD4 percent at 6 months of HAART was 
found to be significantly higher in those children who 
started therapy at CD4 count of more than 500 in 
comparison to those started below 200 (34% vs 
16.4%).This shows that even if HAART is given, the 
response will be poor if started after the immunity is 
significantly damaged.  Children who started therapy at 
clinical stage 4 were found to have very low response 
after 6 months compared to children who started at 
clinical stage 1(8.1% vs 20.8%). This is shows that 
starting treatment after severe manifestation will not 
bring ssignificant change in CD4 response because of the 
already deteriorated immunity. Therefore, starting 
HAART before clinical and/or immunological 
deterioration is important to get good CD4 response with 
the treatment. Similar findings were revealed in different 
studies (11, 12, and 13).  
Compared with other predictors, our analysis 
revealed that initiation of HAART at low CD4 count 
(p<0.001), children with no good adherence and not 
disclosed of their HIV status were having significant 
effect on CD4 count increment at 6months of HAART 





(P<0.05). It was also observed that age had shown a 
borderline effect on immunologic response (p-value of 
0.081), 95% CI (0.955, 1.003).  According to this finding 
(although not significant at the usual 5% level of 
significance), initiation of HAART at a relatively older 
age was followed by a relatively reduced (2%) CD4 
count on the average. In other words initiation of 
HAART at early age seemed to improve the 
immunologic response. This finding is in complete 
agreement with the result of a study undertaken in 
Jimma, Ethiopia,  which showed strong evidence that 
early initiation has a good effect on immunologic 
response (14). This finding is a good reason to have 
diagnostic tests at early age which is one of the major 
challenges in resource-limited areas due to the need to 
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